Visit https://www.peervoice.com/VVA860 to view the entire programme with slides. After completing “Checking In on Checkpoint Inhibitors: Current and Emerging Strategies for High PD-L1–Expressing Tumours in Advanced NSCLC”, participants will be able to: Describe the unmet needs for patients with advanced NSCLC and how checkpoint inhibitors can address these challenges; Evaluate the most recent clinical evidence for current and emerging checkpoint inhibitors in the first-line management of advanced NSCLC with high PD-L1 expression; Discuss how emerging data may impact the treatment algorithm for patients with advanced NSCLC and high PD-L1 expression.